

IDS/ #18
4-19-03

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper or, if this paper is a transmittal letter, every other paper or fee referred to therein, is being facsimile transferred to the Commissioner of Patents & Trademarks at the United States Patent and Trademark Office, Washington, DC 20231, on the date shown below

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

(Date of Transmission)

4/1/03 Date
Pat Campbell Name

Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 3118/1J014US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark X. Sliwkowski

Serial No.: 09/602,800

Art Unit: 1642

Confirmation No.: 1759

Examiner: Anne L. Holleran

Filed: 6/23/00

For: TREATING PROSTATE CANCER WITH ANTI-ERBB2 ANTIBODIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form

PTO-1449 and copies of the documents listed thereon.

PTO-1449 and copies of the documents listed thereon.

All of these documents were either 1) not cited in a foreign counterpart of this application and not known for more than three months, or 2) were first cited in a foreign counterpart of this application not more than three months ago.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any

deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: April 1, 2003



Paul F. Fehlner, Ph.D.

Registration No. 35,135

Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700